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1. INTRODUCTION {#ccr31851-sec-0001}
===============

Atrial septal defect (ASD) is a common congenital heartdisease (CHD) characterized by deficiency of the atrial septal tissue in the region of the fossa ovalis.[1](#ccr31851-bib-0001){ref-type="ref"} There are several types of ASD, and the most frequent type is the ostium secundum ASD (ASD2) that results from an enlarged foramen ovale, inadequate growth of the septum secundum, or excessive absorption of the septum primum.[1](#ccr31851-bib-0001){ref-type="ref"} ASD takes place not only as a sporadic form with no identifiable cause but also as a familial form primarily with an autosomal dominant manner, and the prevalence of familial occurrence is known to be highest for ASD among various CHDs.[2](#ccr31851-bib-0002){ref-type="ref"} This indicates that ASD develops not only as a multifactorial disorder subject to various genetic and environmental factors but also as a single gene disorder.

To date, more than 10 causative genes have been identified for ASD, including *GATA4*.[3](#ccr31851-bib-0003){ref-type="ref"} *GATA4* is an evolutionarily conserved zinc finger transcription factor gene that recognizes the "GATA" motif functioning as an important cis‐element in the promoters of many genes, and plays an essential role in the early development of multiple organs, including the heart, ovary, testis, foregut, liver, and pancreas.[4](#ccr31851-bib-0004){ref-type="ref"} *GATA4*variants have been identified not only in patients with ASD but also in those with various types of CHDs including tetralogy of Fallot (TOF), ventricular septal defect, and atrioventricular septal defect.[5](#ccr31851-bib-0005){ref-type="ref"}, [6](#ccr31851-bib-0006){ref-type="ref"} Furthermore, consistent with the wide expression pattern including the testis, *GATA4* variants have also been found in patients with 46,XY disorder of sex development (DSD) due to impaired testis formation with or without CHD.[6](#ccr31851-bib-0006){ref-type="ref"}, [7](#ccr31851-bib-0007){ref-type="ref"} These findings imply that *GATA4* variants lead to the development of various types of CHD and 46,XY DSD with variable expressivity and reduced penetrance.

Here, we report a *GATA4* variant identified in a family with dominantly inherited ASD2, and clinical and endocrine findings on sex development in two boys with the variant.

2. CASE PRESENTATION {#ccr31851-sec-0002}
====================

The pedigree of this Japanese family is shown in Figure [1](#ccr31851-fig-0001){ref-type="fig"}. The proband (III‐1) was born at 39 weeks of gestation to the mother (II‐2) who was diagnosed as having ASD2 in her childhood and received intracardiac repair (ICR). Allegedly, the maternal grandmother (I‐2) also had ASD2, and the maternal younger sister (II‐4) had TOF. Because of such family history, cardiac assessment was performed for III‐1 at one month of age. Chest X‐ray delineated mildly enlarged pulmonary vessels, and electrocardiography (ECG) revealed incomplete right bundle branch block (iRBBB). Thus, ultrasound cardiography (UCG) was carried out, showing ASD2 and right atrial and ventricular enlargement with moderate pulmonary stenosis (PS). He underwent ICR and pulmonary valvuloplasty at two 7/12 years of age. III‐2 and III‐3 were also found to have similar chest X‐ray findings and iRBBB, and were diagnosed to have ASD2 with right atrial and ventricular enlargement and moderate PS by UCG shortly after birth. III‐2 and III‐3 also received ICR and pulmonary valvuloplasty at five 0/12 and four 3/12 years of age, respectively. Subsequently, although III‐4 was suspected to have patent foramen ovale by fetal UCG at 34 weeks of gestation, she was shown to have no abnormal findings by chest X‐ray, ECG, and UCG.

![The pedigree of a Japanese family examined in this study. The black, gray, and white symbols indicate subjects with clinically confirmed ASD2, those with allegedly suggested but not clinically confirmed ASD2 or TOF, and those without cardiac disease, respectively. The (+) and (--) symbols indicate molecularly confirmed *GATA4* variant‐positive and *GATA4* variant‐negative subjects, respectively](CCR3-6-2229-g001){#ccr31851-fig-0001}

Except for the CHDs, there was no clinically discernible abnormal finding in the ASD2‐positive III‐1, III‐2, and III‐3. They were born at term with normal birth sizes, and exhibited normal growth and mental development. In the yearly follow‐up observations, physical examinations showed no minor anomalies, and routine blood and urine laboratory tests including hepatic and renal function markers indicated normal findings. On the last examinations at 7, 5, and 3 years of age, respectively, they remained healthy without medication, and bone survey and visceral ultrasonographic studies revealed no abnormal findings. The parents and the ASD2‐negative III‐4 were also clinically normal.

We performed whole‐exome sequencing (WES) with SureSelect Human All Exon V6 (Agilent Technologies, Santa Clara, CA, USA), using leukocyte genomic DNA of II‐1, II‐2, III‐2, III‐3, and III‐4. This study was approved by the Institutional Review Board Committee at Hamamatsu University School of Medicine, and performed after obtaining written informed consent. Captured libraries were sequenced by NextSeq 500 (Illumina, San Diego, CA, USA) with 150‐bp paired‐end reads. Reads were aligned to the reference genome (Human GRCh37/hg19), using BWA‐MEM (version 0.7.12) with default parameters. Duplicated reads were removed by Picard (version 2.9.2), and local realignment and base quality recalibration were performed by GATK version 3.7. Variants were identified with the GATK HaplotypeCaller, and variants with minor allele frequencies of \<0.005 in all the following public databases and in‐house database were selected as rare variants: whole genome and WES data for East Asian population in Genome Aggregation Database,[8](#ccr31851-bib-0008){ref-type="ref"} Human Genetic Variation Database,[9](#ccr31851-bib-0009){ref-type="ref"} and allele frequency data of 2049 Japanese individuals.[10](#ccr31851-bib-0010){ref-type="ref"} Final variants were annotated with Annovar.[11](#ccr31851-bib-0011){ref-type="ref"}

Consequently, 34 rare variants including nine variants completely absent from the public and in‐house databases were found to be present in the ASD2‐positive subjects (II‐2, III‐2, and III‐3) and absent from the ASD2‐negative subjects (II‐1 and III‐4) (Table [S1](#ccr31851-sup-0001){ref-type="supplementary-material"}). We next carried out in silico pathogenicity prediction using four different methods, OMIM survey for diseases caused by mutations of the corresponding genes, and UCSC search for tissue expression pattern of the corresponding gene, thereby identifying a heterozygous missense substitution at exon 4 of *GATA4* (GenBank, [NM_002052.4](NM_002052.4):c.851G\>A, p.(R284H); CRCh37, Chr8:11607687) as the most likely candidate variant for ASD2 in this family (Figure [2](#ccr31851-fig-0002){ref-type="fig"}A, Table [S1](#ccr31851-sup-0001){ref-type="supplementary-material"}). This variant was also found in the ASD2‐positive subject III‐1, as well as in II‐2, III‐2, and III‐3 (Figure [2](#ccr31851-fig-0002){ref-type="fig"}B). The R284 residue was highly conserved (Figure [2](#ccr31851-fig-0002){ref-type="fig"}C), and this variant was completely absent from the public and in‐house databases (Figure [2](#ccr31851-fig-0002){ref-type="fig"}D) and was assessed to have high pathogenicity by all the four in silico pathogenic predictions (Figure [2](#ccr31851-fig-0002){ref-type="fig"}E). Furthermore, this variant was found to be reported as the causative variant in a French family with ASD2.[12](#ccr31851-bib-0012){ref-type="ref"} No other candidate variant for CHD was identified.

![Summary of molecular and in silico analyses. A, Structure of the GATA4 protein and the position of the p.(R284H) variant. The GATA4 protein consists of 442 amino acids and harbors two transcription activation domains (TAD1 and TAD2), two zinc finger domains (ZF1 and ZF2), and a single nuclear localization signal (NLS) The p.(R284H) variant resides on ZF2. B, Electrochromatograms showing the c.851G\>A substitution on exon 4 in II‐2, III‐1, III‐2, and III‐3 (indicated with red asterisks). The primers used are as follows: forward, 5\'‐CGTGATTCCTCACTCTCTGC‐3\'; and reverse, 5\'‐TCCAAATGAACAGCCAATTTT‐3\'. C, Conservation of the R284 residue among different species. D, Complete absence of p.(R284H) in the public and in‐house databases. The URLs utilized in this study are shown in the footnotes of Table [S1](#ccr31851-sup-0001){ref-type="supplementary-material"}. E, In silico pathogenic analyses for p.(R284H). The URLs utilized in this study are shown in the footnotes of Table [S1](#ccr31851-sup-0001){ref-type="supplementary-material"}](CCR3-6-2229-g002){#ccr31851-fig-0002}

After identification of the *GATA4* variant, we investigated the status of male sex development in two variant‐positive subjects (III‐1 and III‐2) (Table [1](#ccr31851-tbl-0001){ref-type="table"}). Physical examination showed normal male external genitalia with intrascrotal testes of \~2 mL. Chromosome analysis showed a 46,XY karyotype. Gonadotropin‐releasing hormone (GnRH) tests revealed normal basal and GnRH‐stimulated serum luteinizing hormone (LH) values and mildly increased basal and GnRH‐stimulated serum follicle‐stimulating hormone (FSH) values in both subjects. Human chorionic gonadotropin stimulation tests indicated sufficient serum testosterone productions. Serum anti‐Müllerian hormone (AMH) values were obviously low in both subjects.

###### 

Clinical and endocrine findings in male subjects III‐1 and III‐2 with a *GATA4* variant

                          III‐1                                                                    III‐2
  ----------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------
  Age at examination, y   7                                                                        5
  Clinical findings                                                                                
  External genitalia      Normal                                                                   Normal
  Other findings          None                                                                     None
  Serum hormone values                                                                             
  LH (mIU/mL)             0.4 (0.2‐1.9) → 4.7 (1.1‐6.0)[a](#ccr31851-note-0004){ref-type="fn"}     0.2 (0.2‐1.9) → 5.3 (1.1‐6.0)[a](#ccr31851-note-0004){ref-type="fn"}
  FSH (mIU/mL)            3.3 (\<0.3‐2.4) → 8.2 (1.9‐7.6)[a](#ccr31851-note-0004){ref-type="fn"}   3.2 (\<0.3‐2.4) → 18.5 (1.9‐7.6)[a](#ccr31851-note-0004){ref-type="fn"}
  Testosterone (ng/dL)    5.3 (3‐13) → 226.2 (\>200)[b](#ccr31851-note-0005){ref-type="fn"}        \<5 (3‐13) → 454.8 (\>200)[b](#ccr31851-note-0005){ref-type="fn"}
  AMH (ng/mL)             16.3 (43.3‐79.3)                                                         17.3 (43.3‐79.3)

AMH: anti‐Müllerian hormone; ASD: atrial septal defect; CHD: congenital heart disease; FSH: follicle‐stimulating hormone; LH: luteinizing hormone.

The values in parentheses represent the age‐ and sex‐matched normal range.[17](#ccr31851-bib-0017){ref-type="ref"}, [18](#ccr31851-bib-0018){ref-type="ref"}

Peak value during a GnRH stimulation test (GnRH 100 μg/m^2^ bolus iv; blood sampling at 0, 30, 60, 90, and 120 min).

Basal and stimulated values in an hCG test (3,000 IU/m^2^ per dose \[max. 5,000 IU\] im for three consecutive days; blood sampling on days 1 and 4).
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3. DISCUSSION {#ccr31851-sec-0003}
=============

We identified a rare*GATA4*variant co‐segregating with ASD2 in this Japanese family. In this regard, the absence of this variant in the public and in‐house databases, high pathogenicity predicted by the four in silico analyses, and gene information by OMIM and UCSC survey (Table [S1](#ccr31851-sup-0001){ref-type="supplementary-material"}), in conjunction with the previous description of the same variant in a French family with ASD2,[12](#ccr31851-bib-0012){ref-type="ref"} indicate that this variant is responsible for the development of ASD2 in this Japanese family. According to the ACMG Standards and Guidelines,[13](#ccr31851-bib-0013){ref-type="ref"} this variant is regarded as a "likely pathogenic variant," because this variant is positive for PS1 (same amino acid change as an established pathogenic variant), PM2 (absent from controls), PP1 (co‐segregation with disease phenotype in multiple affected family members), and PP3 (multiple lines of computational evidence in support of a deleterious effect).

ASD2 with PS was the salient cardiac phenotype in this family, although the maternal sister (II‐4) allegedly had TOF. Previous studies have also revealed various*GATA4* variants in familial forms of ASD2 with and without PS.[5](#ccr31851-bib-0005){ref-type="ref"}, [12](#ccr31851-bib-0012){ref-type="ref"} Thus, it is likely that *GATA4* variants frequently cause ASD with and without PS and occasionally lead to other types of CHDs, depending on the effects of other multiple genetic and environmental factors.

No clinically recognizable extra‐cardiac feature was identified in the ASD2‐positive subjects in this family, although it might be possible that some extra‐cardiac feature(s) have remained undetected. This would primarily be consistent with the*GATA4* variant in this family, because previous studies have shown that *GATA4* variants, though they are occasionally accompanied by extra‐cardiac features such as 46,XY DSD[6](#ccr31851-bib-0006){ref-type="ref"}, [7](#ccr31851-bib-0007){ref-type="ref"} and congenital diaphragmatic hernia,[14](#ccr31851-bib-0014){ref-type="ref"} usually lead to isolated CHDs (primarily ASD2). However, lack of extra‐cardiac features is not a common finding in CHDs in general. Rather, CHDs are often associated with extra‐cardiac features, such as brain, skeletal, respiratory, gastrointestinal, and/or genitourinary malformations.[15](#ccr31851-bib-0015){ref-type="ref"}, [16](#ccr31851-bib-0016){ref-type="ref"} In this regard, further studies will serve to clarify underlying causes (eg, single gene variants, oligogenic variants, and multifactorial factors, with variable expressivity and reduced penetrance) of CHDs with and without extra‐cardiac features. Furthermore, such clarification based on both clinical and genetic studies will permit better clinical management and genetic counseling in CHD‐positive patients and their relatives.

Clinical and endocrine studies were performed for male sex development in two variant‐positive boys. In this regard, although well‐masculinized external genitalia and normal LH and testosterone productions indicate well‐preserved Leydig cell function, slightly increased FSH values and obviously low AMH values may suggest more or less compromised Sertoli cell function in the two boys.[17](#ccr31851-bib-0017){ref-type="ref"}, [18](#ccr31851-bib-0018){ref-type="ref"}, [19](#ccr31851-bib-0019){ref-type="ref"} In particular, serum AMH is s a reliable marker of Sertoli cell function.[18](#ccr31851-bib-0018){ref-type="ref"} However, since GATA4 binds to the *AMH* promoter and enhances *AMH* expression synergically with NR5A1,[6](#ccr31851-bib-0006){ref-type="ref"} the *GATA4* p.(R284H) variant may have primarily impaired *AMH* expression, with no clinically discernible deleterious effect on other Sertoli cell function including Sertoli‐germ cell interaction. Indeed, male subjects with the same p.(R284H) variant in the French family are fertile, although they have ASD2.[12](#ccr31851-bib-0012){ref-type="ref"} Thus, the deleterious effect of *GATA4* p.(R284H) variant on testicular function would remain at a subclinical level, if any. It should be pointed out, however, that *GATA4* variants have been identified in five patients with 46,XY DSD.[6](#ccr31851-bib-0006){ref-type="ref"}, [7](#ccr31851-bib-0007){ref-type="ref"} Thus, it is likely that *GATA4* variants lead to 46,XY DSD in rather exceptional subjects, depending on the residual activity of the *GATA4* variants and the predisposing genetic and environmental factors of the variant‐positive subjects.

4. CONCLUSION {#ccr31851-sec-0004}
=============

We identified a *GATA4* variant in a family with dominantly inherited ASD2 by WES. The results, together with the previous findings, imply that *GATA4*variants primarily lead to congenital heart disease and rarely result in extra‐cardiac features including 46,XY DSD.
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